Sanofi Forecast, price target & analysts
Sanofi Target price 2025 - Analyst rating & recommendation
Sanofi Classifications & Recommendation:
Sanofi Price Target
| Target Price | €118.32 |
| Price | €106.22 |
| Potential |
11.40%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Sanofi 2026 .
The average Sanofi target price is €118.32.
This is
11.40%
register free of charge
€127.00
19.56%
register free of charge
€100.00
5.86%
register free of charge
|
|
| A rating was issued by 24 analysts: 20 Analysts recommend Sanofi to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sanofi stock has an average upside potential 2026 of
11.40%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion € | 41.08 | 47.08 |
| 8.63% | 14.60% | |
| EBITDA Margin | 31.98% | 30.75% |
| 1.42% | 3.83% | |
| Net Margin | 13.55% | 18.08% |
| 5.17% | 33.44% |
18 Analysts have issued a sales forecast Sanofi 2025 . The average Sanofi sales estimate is
This results in the following potential growth metrics:
15 Analysts have issued an Sanofi EBITDA forecast 2025. The average Sanofi EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Sanofi Analysts have issued a net profit forecast 2025. The average Sanofi net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 4.44 | 6.79 |
| 3.02% | 52.93% | |
| P/E | 15.61 | |
| EV/Sales | 3.05 |
9 Analysts have issued a Sanofi forecast for earnings per share. The average Sanofi <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Sanofi stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current Sanofi Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Jan 06 2025 |
| BNP PARIBAS EXANE |
Locked
➜
Locked
|
Locked | Jan 05 2025 |
| BANCO SANTANDER |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| ODDO BHF |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| TD COWEN |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| LEERINK PARTNERS |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Nov 25 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jan 06 2025 |
|
Locked
BNP PARIBAS EXANE:
Locked
➜
Locked
|
Jan 05 2025 |
|
Locked
BANCO SANTANDER:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
ODDO BHF:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
TD COWEN:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
LEERINK PARTNERS:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Nov 25 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
